MEDICLIN AG (DE:MED)
XETRA:MED
Top Page
MEDICLIN
(XETRA:MED)
Select Model
Select Model
Rating:65Neutral
Price Target:
€4.00
▲(11.11% Upside)
Action:DowngradedDate:03/29/26
The score is driven primarily by solid cash-flow performance, tempered by balance-sheet leverage and earnings/margin volatility. Valuation is a strong positive due to the very low P/E, while technical indicators are mixed and do not add meaningful momentum support.
Positive Factors
Cash generation
Consistent operating cash flow and a material FCF rebound in 2025 provide durable internal funding for capex, working capital and debt reduction. Reliable cash generation enhances resilience to demand shocks, supports reinvestment and reduces reliance on external financing over months to years.
Negative Factors
High leverage
Historically elevated leverage (>2x) reduces financial flexibility, increasing interest costs and constraining the ability to absorb downturns or fund growth without new financing. Partial de-risking in 2025 helps, but the balance sheet remains a medium-term constraint on strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent operating cash flow and a material FCF rebound in 2025 provide durable internal funding for capex, working capital and debt reduction. Reliable cash generation enhances resilience to demand shocks, supports reinvestment and reduces reliance on external financing over months to years.
Read all positive factors
MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€163.40M
Dividend Yield1.12%
Average Volume (3M)5.25K
Price to Earnings (P/E)6.9
Beta (1Y)0.25
Revenue Growth4.90%
EPS GrowthN/A
CountryDE
Employees7,292
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding47,500,000
10 Day Avg. Volume4,347
30 Day Avg. Volume5,253
Financial Highlights & Ratios
PEG Ratio1.79
Price to Book (P/B)0.71
Price to Sales (P/S)0.22
P/FCF Ratio3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)€797.78M
MEDICLIN Business Overview & Revenue Model
Company Description
MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute, Acute, and Other Activities segments. It offers medical services in the areas of neurology, psychosomatics, orthopaedics, internal medicine, cardio...
How the Company Makes Money
MEDICLIN primarily makes money by operating healthcare facilities and billing for the medical services delivered at those sites. Key revenue streams include (1) inpatient acute-care treatment revenue generated when patients are admitted and treate...
MEDICLIN Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
44
Neutral
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 784.49M | 748.80M | 730.10M | 704.70M | 673.10M |
| Gross Profit | 113.81M | 623.00M | 594.60M | 571.90M | 551.00M |
| EBITDA | 98.66M | 106.41M | 101.27M | 91.80M | 85.43M |
| Net Income | 25.49M | 24.84M | -10.78M | 9.44M | 1.46M |
Balance Sheet | |||||
| Total Assets | 879.69M | 905.91M | 880.50M | 916.11M | 881.24M |
| Cash, Cash Equivalents and Short-Term Investments | 72.18M | 107.56M | 115.29M | 88.04M | 133.48M |
| Total Debt | 390.83M | 464.13M | 479.82M | 502.67M | 439.96M |
| Total Liabilities | 630.06M | 683.17M | 684.47M | 706.79M | 698.22M |
| Stockholders Equity | 248.95M | 222.51M | 195.92M | 209.21M | 183.28M |
Cash Flow | |||||
| Free Cash Flow | 51.44M | 35.88M | 40.43M | 8.62M | 64.96M |
| Operating Cash Flow | 99.87M | 80.57M | 78.00M | 34.64M | 81.97M |
| Investing Cash Flow | -37.14M | -15.13M | -9.51M | -6.24M | -7.09M |
| Financing Cash Flow | -97.40M | -73.16M | -45.48M | -56.17M | -55.26M |
MEDICLIN Technical Analysis
Negative
3.60
Price Trends
3.69
Negative
3.68
Negative
3.41
Positive
Market Momentum
-0.06
Negative
44.77
Neutral
47.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Negative. The current price of 3.6 is above the 20-day moving average (MA) of 3.52, below the 50-day MA of 3.69, and above the 200-day MA of 3.41, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.77 is Neutral, neither overbought nor oversold. The STOCH value of 47.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MED.
MEDICLIN Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €292.50M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
73 Outperform | €145.20M | 8.54 | 22.77% | ― | 0.21% | 7.53% | |
65 Neutral | €163.40M | 6.90 | 10.71% | 1.12% | 4.90% | ― | |
57 Neutral | €830.04M | 20.44 | 2.63% | 0.77% | 9.10% | -15.07% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
41 Neutral | €23.91M | -1.84 | 22.85% | ― | 6.87% | -94.85% |
* General Sector Average
DE:MED
MEDICLIN
3.54
0.68
23.78%
DE:RHK
RHON-KLINIKUM AG
12.40
-2.58
-17.21%
DE:MAK
MATERNUS-Kliniken AG
1.14
-0.20
-14.93%
DE:LIK
Limes Schlosskliniken AG
484.00
202.00
71.63%
DE:JTH0
Gesundheitswelt Chiemgau AG
12.00
-0.08
-0.66%
DE:M12
M1 Kliniken AG
15.66
1.14
7.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.